Denis Chem Lab Ltd
Incorporated in 1982, Denis Chem Lab Ltd does manufacturing of Pharmaceuticals Transfusion Solution in Bottles[1]
- Market Cap ₹ 228 Cr.
- Current Price ₹ 164
- High / Low ₹ 175 / 73.0
- Stock P/E 24.8
- Book Value ₹ 53.9
- Dividend Yield 1.22 %
- ROCE 16.1 %
- ROE 11.3 %
- Face Value ₹ 10.0
Pros
- Company has reduced debt.
- Company is almost debt free.
- Company has delivered good profit growth of 29.7% CAGR over last 5 years
- Company has been maintaining a healthy dividend payout of 38.2%
- Debtor days have improved from 88.9 to 71.0 days.
- Company's working capital requirements have reduced from 59.5 days to 43.7 days
Cons
- Stock is trading at 3.04 times its book value
- The company has delivered a poor sales growth of 8.48% over past five years.
- Promoter holding is low: 39.0%
- Company has a low return on equity of 8.45% over last 3 years.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Bulk Drugs & Formln
Quarterly Results
Figures in Rs. Crores
Profit & Loss
Figures in Rs. Crores
Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | TTM | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
39 | 55 | 67 | 75 | 98 | 112 | 107 | 123 | 135 | 109 | 136 | 161 | 168 | |
35 | 49 | 60 | 66 | 89 | 98 | 95 | 110 | 120 | 99 | 122 | 142 | 147 | |
Operating Profit | 4 | 6 | 6 | 9 | 8 | 14 | 12 | 14 | 15 | 10 | 14 | 19 | 21 |
OPM % | 11% | 11% | 9% | 12% | 9% | 12% | 11% | 11% | 11% | 9% | 11% | 12% | 12% |
0 | 0 | 0 | 0 | 0 | 1 | 1 | 2 | 0 | 0 | 1 | 1 | 1 | |
Interest | 2 | 2 | 3 | 5 | 7 | 6 | 5 | 3 | 3 | 2 | 1 | 1 | 1 |
Depreciation | 1 | 1 | 1 | 4 | 6 | 7 | 6 | 6 | 7 | 6 | 6 | 8 | 9 |
Profit before tax | 1 | 3 | 2 | 0 | -3 | 2 | 2 | 6 | 6 | 3 | 9 | 11 | 13 |
Tax % | 36% | 34% | 41% | 78% | -30% | 37% | -5% | -7% | 26% | 27% | 30% | 28% | |
1 | 2 | 1 | 0 | -4 | 1 | 2 | 6 | 4 | 2 | 6 | 8 | 9 | |
EPS in Rs | 1.55 | 3.11 | 1.17 | 0.07 | -4.16 | 0.89 | 1.54 | 4.58 | 3.03 | 1.63 | 4.51 | 5.66 | 6.63 |
Dividend Payout % | 29% | 18% | 0% | 0% | 0% | 0% | 0% | 22% | 0% | 46% | 33% | 35% |
Compounded Sales Growth | |
---|---|
10 Years: | 11% |
5 Years: | 8% |
3 Years: | 6% |
TTM: | 6% |
Compounded Profit Growth | |
---|---|
10 Years: | 17% |
5 Years: | 30% |
3 Years: | 23% |
TTM: | 15% |
Stock Price CAGR | |
---|---|
10 Years: | 20% |
5 Years: | 21% |
3 Years: | 40% |
1 Year: | 118% |
Return on Equity | |
---|---|
10 Years: | 7% |
5 Years: | 9% |
3 Years: | 8% |
Last Year: | 11% |
Balance Sheet
Figures in Rs. Crores
Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Sep 2023 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Equity Capital | 1 | 2 | 3 | 9 | 9 | 12 | 14 | 14 | 14 | 14 | 14 | 14 | 14 |
Reserves | 5 | 7 | 6 | 8 | 3 | 18 | 36 | 43 | 45 | 48 | 53 | 58 | 61 |
11 | 17 | 31 | 48 | 44 | 37 | 25 | 23 | 14 | 9 | 3 | 2 | 2 | |
8 | 10 | 12 | 17 | 28 | 27 | 26 | 26 | 25 | 22 | 27 | 25 | 34 | |
Total Liabilities | 26 | 35 | 52 | 81 | 85 | 94 | 101 | 106 | 97 | 92 | 96 | 99 | 111 |
9 | 10 | 9 | 42 | 40 | 44 | 40 | 50 | 46 | 41 | 42 | 35 | 37 | |
CWIP | 0 | 0 | 9 | 0 | 10 | 1 | 5 | 0 | 0 | 0 | 0 | 2 | 1 |
Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
16 | 25 | 34 | 39 | 35 | 49 | 56 | 55 | 52 | 51 | 55 | 62 | 73 | |
Total Assets | 26 | 35 | 52 | 81 | 85 | 94 | 101 | 106 | 97 | 92 | 96 | 99 | 111 |
Cash Flows
Figures in Rs. Crores
Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
2 | -1 | -2 | 14 | 21 | 7 | 11 | 8 | 13 | 8 | 17 | 16 | |
-0 | -1 | -9 | -28 | -13 | -1 | -16 | -2 | -2 | -1 | -10 | -11 | |
-2 | 4 | 12 | 13 | -7 | -0 | 1 | -5 | -14 | -6 | -7 | -4 | |
Net Cash Flow | -1 | 1 | 0 | -1 | 1 | 5 | -4 | 1 | -3 | 1 | -0 | 1 |
Ratios
Figures in Rs. Crores
Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Debtor Days | 104 | 111 | 91 | 123 | 85 | 104 | 105 | 106 | 94 | 110 | 85 | 71 |
Inventory Days | 39 | 40 | 37 | 40 | 39 | 35 | 52 | 50 | 51 | 60 | 50 | 39 |
Days Payable | 56 | 60 | 53 | 81 | 119 | 136 | 150 | 102 | 108 | 103 | 99 | 79 |
Cash Conversion Cycle | 87 | 90 | 75 | 81 | 4 | 3 | 8 | 55 | 37 | 67 | 36 | 31 |
Working Capital Days | 43 | 67 | 100 | 61 | 4 | 39 | 47 | 59 | 55 | 81 | 54 | 44 |
ROCE % | 19% | 22% | 16% | 11% | 5% | 13% | 9% | 11% | 11% | 6% | 14% | 16% |
Documents
Announcements
- Declaration Of Non- Applicability Of Large Entity Framework 12 Apr
- Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure A 12 Apr
- PCS Certificate In Terms Of Reg. 40(9) Of SEBI (LODR), Regulations, 2015 For The Financial Year Ended On 31St March, 2024. 12 Apr
-
Compliances-Compliances Certificate For The Period Ended 31St March, 2024
12 Apr - Submitting Compliances Certificate under Reg 7(2) of Listing Regulations for the Financial Year ended 31st March, 2024.
-
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
12 Apr - Reg. 74(5) of SEBI(DP) Reg,2018 we are hereby submitting certificate issued by Link Intime India Private Limited, Registrar and Share Transfer Agent of the company …
Annual reports
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
-
Financial Year 2010
from bse
-
Financial Year 2009
from bse
Business Overview:[1]
DCLL manufactures and markets sterile Intravenous injectibles in Glass and Plastic Bottles for human and veterinary consumption. It also manufactures products on contract basis for multinational pharmaceutical companies who market them under their own brands. Company has a fully equipped in-house Quality Control Laboratory having different interdepartments for Chemical Testing, Physico-Chemical Testing, Microbiological Testing, Pyrogens Testing, Sterility Testing and Toxicity Testing. All raw materials, packaging materials, in process testing and finished stocks are tested in-house.